Skip to main content
Erschienen in: Familial Cancer 4/2009

01.12.2009

Conflict between values and technology: perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer

verfasst von: Gwendolyn P. Quinn, Susan T. Vadaparampil, Lindsey M. King, Cheryl A. Miree, Sue Friedman

Erschienen in: Familial Cancer | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Members of families affected by hereditary cancer are often concerned about passing on risk to offspring. Preimplantation genetic diagnosis is a procedure performed to identify embryos that inherit mutations placing them at risk for hereditary conditions. Little is known about attitudes toward the use of this technology among individuals at risk for hereditary breast and ovarian cancer. We sought to determine high risk women’s attitudes. This study is a qualitative examination of comments from women who participated in an online survey regarding knowledge and attitudes of preimplantation genetic diagnosis among individuals affected by hereditary breast and ovarian cancer. More than half the respondents held less favorable attitudes about the use of preimplantation genetic diagnosis for hereditary breast and ovarian cancer for both themselves and others. However, among the women who felt favorable about its usage, the majority said it became a new option for them to pursue parenthood whereas previously they had opted to not have a biological child. The high percentage of respondents who have never heard of preimplantation genetic diagnosis and who were in favor of this technology for hereditary breast and ovarian cancer indicates the need for educational campaigns to increase awareness and provide information about the procedure, access and affordability. Further research is needed to determine how this population would like this information presented to them and how best to instruct health care professionals to present this topic to women who do not know to ask about it.
Literatur
4.
Zurück zum Zitat Menon U, Harper J, Sharma A, Fraser L, Burnell M, ElMasry K, Rodeck C, Jacobs I (2007) Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod 22(6):1573–1577. doi:10.1093/humrep/dem055 CrossRefPubMed Menon U, Harper J, Sharma A, Fraser L, Burnell M, ElMasry K, Rodeck C, Jacobs I (2007) Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod 22(6):1573–1577. doi:10.​1093/​humrep/​dem055 CrossRefPubMed
7.
Zurück zum Zitat Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM (2007) Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer 7:179–186CrossRefPubMed Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM (2007) Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer 7:179–186CrossRefPubMed
8.
Zurück zum Zitat Quinn G, Vadaparampil S, Wilson C et al (2009) Attitudes of high-risk women toward preimplantation genetic diagnosis. Fertil Steril 91:2361–2368CrossRefPubMed Quinn G, Vadaparampil S, Wilson C et al (2009) Attitudes of high-risk women toward preimplantation genetic diagnosis. Fertil Steril 91:2361–2368CrossRefPubMed
11.
Zurück zum Zitat Lancaster JM, Wiseman RW, Berchuck A (1995) An inevitable dilemma: prenatal testing mutations in the BRCA1 breast-ovarian cancer susceptibility gene. Obstet Gynecol 87:306–309CrossRef Lancaster JM, Wiseman RW, Berchuck A (1995) An inevitable dilemma: prenatal testing mutations in the BRCA1 breast-ovarian cancer susceptibility gene. Obstet Gynecol 87:306–309CrossRef
12.
Zurück zum Zitat Smith KR, Ellington L, Chan AY, Croyle RT, Botkin JR (2004) Fertility intentions following testing for a BRCA1 gene mutation. Cancer Epidemiol Biomarkers Prev 13(5):733–740PubMed Smith KR, Ellington L, Chan AY, Croyle RT, Botkin JR (2004) Fertility intentions following testing for a BRCA1 gene mutation. Cancer Epidemiol Biomarkers Prev 13(5):733–740PubMed
13.
Zurück zum Zitat Ao A, Wells D, Handyside AJ, Winston RML, Delhanty JDA (1998) Preimplantation genetic diagnosis of inherited cancer: familial adenomatous polyposis coli. Genetics 15(3):140–144 Ao A, Wells D, Handyside AJ, Winston RML, Delhanty JDA (1998) Preimplantation genetic diagnosis of inherited cancer: familial adenomatous polyposis coli. Genetics 15(3):140–144
15.
Zurück zum Zitat Handyside AH, Kontogianni EH, Hardy K, Winston RML (1990) Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. Nature 344:768–770CrossRefPubMed Handyside AH, Kontogianni EH, Hardy K, Winston RML (1990) Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. Nature 344:768–770CrossRefPubMed
17.
Zurück zum Zitat Verlinsky Y, Ginsburg N, Lifchez A, Valle J, Moise J, Strom C (1990) Analysis of the first polar body: preconception genetic diagnosis. Hum Reprod 5:826–829PubMed Verlinsky Y, Ginsburg N, Lifchez A, Valle J, Moise J, Strom C (1990) Analysis of the first polar body: preconception genetic diagnosis. Hum Reprod 5:826–829PubMed
18.
Zurück zum Zitat Zitner A (2002) The nation: cloning receives a makeover politics: nuances of language helped reframe the debate and derail an all-out ban in congress. LA Times, p A1 Zitner A (2002) The nation: cloning receives a makeover politics: nuances of language helped reframe the debate and derail an all-out ban in congress. LA Times, p A1
20.
Zurück zum Zitat Testart J, Sele B (1995) Towards an efficient medical eugenics: is the desirable always the feasible? Hum Reprod 10(12):3086–3090PubMed Testart J, Sele B (1995) Towards an efficient medical eugenics: is the desirable always the feasible? Hum Reprod 10(12):3086–3090PubMed
22.
Zurück zum Zitat Simpson JL (2001) Celebrating preimplantation genetic diagnosis of p53 mutations in Li-Fraumeni syndrome. Reprod Biomed Online 3:2–3PubMedCrossRef Simpson JL (2001) Celebrating preimplantation genetic diagnosis of p53 mutations in Li-Fraumeni syndrome. Reprod Biomed Online 3:2–3PubMedCrossRef
23.
Zurück zum Zitat Hudson K (2002) Public awareness and attitudes about reproductive genetic technology. Genetics and Public Policy Center, Washington, DC Hudson K (2002) Public awareness and attitudes about reproductive genetic technology. Genetics and Public Policy Center, Washington, DC
27.
Zurück zum Zitat Guba EG (1978) Toward a methodology of naturalistic inquiry in educational evaluation. University of California, Los Angeles Guba EG (1978) Toward a methodology of naturalistic inquiry in educational evaluation. University of California, Los Angeles
28.
Zurück zum Zitat Patton MQ (2002) Qualitative research and evaluation methods. Thousand Oaks, Sage Publications Patton MQ (2002) Qualitative research and evaluation methods. Thousand Oaks, Sage Publications
29.
Zurück zum Zitat Dye JF, Schatz IM, Rosenberg BA, Coleman ST (2000) Constant comparison method: a kaleidoscope of data. Qual Rep 4:1–2 Dye JF, Schatz IM, Rosenberg BA, Coleman ST (2000) Constant comparison method: a kaleidoscope of data. Qual Rep 4:1–2
30.
Zurück zum Zitat Shahine LK, Kuppermann M, Davis G, Creasman J, Cedars MI (2008) Patient willingness to participate in a clinical trial with preimplantation genetic diagnosis. Fertil Steril 89(4):879–884CrossRefPubMed Shahine LK, Kuppermann M, Davis G, Creasman J, Cedars MI (2008) Patient willingness to participate in a clinical trial with preimplantation genetic diagnosis. Fertil Steril 89(4):879–884CrossRefPubMed
32.
Zurück zum Zitat Kalfoglou AL, Scott J, Hudson K (2005) PGD patients’ and providers’ attitudes to the use and regulation of preimplantation genetic diagnosis. Reprod Biomed Online 11:486–496PubMed Kalfoglou AL, Scott J, Hudson K (2005) PGD patients’ and providers’ attitudes to the use and regulation of preimplantation genetic diagnosis. Reprod Biomed Online 11:486–496PubMed
33.
Zurück zum Zitat Greendale K, Pyeritz RE (2001) Empowering primary care health professionals in medical genetics: How soon? How fast? How far? Am J Med Genet C Semin Med Genet 106(3):223–232. doi:10.1002/ajmg.10010 CrossRef Greendale K, Pyeritz RE (2001) Empowering primary care health professionals in medical genetics: How soon? How fast? How far? Am J Med Genet C Semin Med Genet 106(3):223–232. doi:10.​1002/​ajmg.​10010 CrossRef
35.
Zurück zum Zitat Wonderlick AL, Fine BA (1997) Knowledge of breast cancer genetics among breast cancer patients and first-degree relatives of affected individuals. J Genet Couns 6(2):111–130CrossRef Wonderlick AL, Fine BA (1997) Knowledge of breast cancer genetics among breast cancer patients and first-degree relatives of affected individuals. J Genet Couns 6(2):111–130CrossRef
36.
Zurück zum Zitat Donelle L, Loffman-Goetz L, Clarke JN (2004) Portrayal of genetic risk for breast cancer. Women Health 49(4):93–111 Donelle L, Loffman-Goetz L, Clarke JN (2004) Portrayal of genetic risk for breast cancer. Women Health 49(4):93–111
Metadaten
Titel
Conflict between values and technology: perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer
verfasst von
Gwendolyn P. Quinn
Susan T. Vadaparampil
Lindsey M. King
Cheryl A. Miree
Sue Friedman
Publikationsdatum
01.12.2009
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2009
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9263-7

Weitere Artikel der Ausgabe 4/2009

Familial Cancer 4/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.